Andrea S. Blevins Primeau, PhD, MBA

Andrea S. Blevins Primeau, PhD, MBA, is a freelance medical writer and editor based in central Pennsylvania. She enjoys writing about a variety of topics including oncology, cardiovascular disease, and autoimmune disorders. Previously, she conducted research investigating the role of pharmacogenetics on the efficacy of oncologic therapies.

All articles by Andrea S. Blevins Primeau, PhD, MBA

CD33 positivity and MPC-1 negativity appear to be associated with worse outcomes in patients with multiple myeloma treated with bortezomib as induction therapy.

Skin Cancer

Low Incidence of Skin Cancer After Liver Transplant in Non-White Patients

Andrea S. Blevins Primeau, PhD, MBA

April 29, 2021

Because of immunosuppressive therapy following liver transplantation, de novo malignancies can occur, and the most common are skin cancers.

A phase 3 trial looking at nivolumab and ipilimumab in advanced melanoma has reported increased survival with the combination, but notable toxicities.

Skin Cancer

BEMPEG Plus Nivolumab Induces Durable Responses in Metastatic Melanoma

Andrea S. Blevins Primeau, PhD, MBA

November 16, 2020

BEMPEG combined with nivolumab resulted in deep and durable responses among patients with treatment-naive metastatic melanoma, according to phase 2 data.

An FDA pilot program to promote transparency in clinical studies falls short of similar efforts by its European and Canadian counterparts.

Practice Management

The Effect of the COVID-19 Pandemic on Telehealth

Andrea S. Blevins Primeau, PhD, MBA

August 4, 2020

Regulations on telehealth services were rapidly deregulated early into the COVID-19 pandemic, but questions remain about quality of care and patient disparities.

Researchers found that cells resistant to both BRAF inhibition and combination inhibition were sensi

Skin Cancer

Continuous Dosing of BRAF/MEK Inhibition Superior to Intermittent Dosing in Melanoma

Andrea S. Blevins Primeau, PhD, MBA

May 14, 2020

Continuous dosing of dabrafenib-trametinib resulted in prolonged PFS compared with intermittent dosing in advanced BRAF-mutated advanced melanoma.

Skin Cancer

Atezolizumab Plus BRAF/MEK Inhibition Prolonged PFS in Melanoma

Andrea S. Blevins Primeau, PhD, MBA

May 7, 2020

Atezolizumab plus cobimetinib and vemurafenib prolonged PFS in unresectable or metastatic melanoma compared with placebo and BRAF/MEK inhibition in the phase 3 IMspire150 trial.

General Dermatology

Selumetinib Deemed Effective in Pediatric Inoperable Plexiform Neurofibromas

Andrea S. Blevins Primeau, PhD, MBA

April 22, 2020

A phase 2 trial demonstrated tumor shrinkage and improvement in reported outcomes in children with inoperable plexiform neurofibromas associated with neurofibromatosis type 1.

Next post in General Dermatology

Andrea S. Blevins Primeau, PhD, MBA

All articles by Andrea S. Blevins Primeau, PhD, MBA

Low Incidence of Skin Cancer After Liver Transplant in Non-White Patients

BEMPEG Plus Nivolumab Induces Durable Responses in Metastatic Melanoma

The Effect of the COVID-19 Pandemic on Telehealth

Continuous Dosing of BRAF/MEK Inhibition Superior to Intermittent Dosing in Melanoma

Atezolizumab Plus BRAF/MEK Inhibition Prolonged PFS in Melanoma

Selumetinib Deemed Effective in Pediatric Inoperable Plexiform Neurofibromas

Combination Bexarotene, Photochemotherapy Effective for Cutaneous T-Cell Lymphoma in Asian Patients